Kidney Transplantation

Calcineurin inhibitor-free immunosuppression improves graft outcome

Published in Clinical Trials Week, December 6th, 2004

Calcineurin inhibitor (CNI)-free immunosuppression is associated with improved outcome in kidney transplant recipients.

Researchers in the United States "performed a randomized prospective trial" comparing CNI-free "to CNI-based immunosuppression to determine the impact on renal function, structure and gene expression."

"Sixty-one kidney recipients treated with basiliximab mycophenolate mofetil (MMF) and prednisone (P) were randomly assigned to concentration-controlled sirolimus or cyclosporine," explained S.M. Flechner and coauthors at the Cleveland Clinic Foundation. "Two years post-transplant 55 patients underwent renal function studies, 48 (87%)...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Trials Week

Source: Clinical Trials Week (2004-12-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry